The North America anaplastic astrocytoma treatment market is benefiting from investment in clinical trials and molecularly guided cancer care. Research into tumor genetics and targeted therapies is supporting efforts to identify more individualized treatment options. The anaplastic astrocytoma treatment market was valued at US$ 382.15 million in 2025 and is expected to reach US$ 680.74 million...